Otonomy’s negative Phase III readout calls into question the utility of targeting the glucocorticoid receptor to treat Meniere disease.  There are no approved drugs to treat the disorder, which is caused by the buildup of...

Day traders have long used Reddit forums, chat rooms and Twitter to talk up biotech stocks, but it’s unlikely they could organize in sufficient numbers to move a stock on the scale of GameStop....

While it’s too early to say whether 2020’s record year of fund-raising constitutes a “new normal,” there’s consensus among buysiders and bankers that a cheap money environment will continue in 2021 as...

Galapagos’ latest move to expand its early fibrosis pipeline, via a deal with Polish biotech OncoArendi, gives the company access to a new fibrosis-blocking immune mechanism.  Through the exclusive collaboration and licensing agreement, Galapagos N.V....

Connect raises $115M C round, eyes pivotal trialsRA Capital’s Derek DiRocco will join the board of Suzhou Connect Biopharmaceuticals Ltd. after the firm led the Chinese biotech’s $115 million series C round.  Additional new investors Lilly...

Sanofi and AstraZeneca are on track to deliver an RSV-preventing mAb that would be more accessible and possibly more effective than Synagis in infants. In a New England Journal of Medicine paper published on Wednesday,...

Investors expect the massive inflows to biotech to continue over the next quarter as the sector is viewed as a top defensive pick in a struggling global economy that is unlikely to improve until the...

Biotech tumbles as U.S. indexes plunge Biotech indexes fell along with the broader markets Thursdays in a sell-off sparked by fears of an increase in COVID-19 infections. The NASDAQ Composite, S&P 500 and Dow Jones...

The NASDAQ Biotechnology Index rose 168.42, or 4%, to 4,201.88 on Monday, reaching an all-time high on the back of substantial inflows into the sector. Twenty-eight companies gained double-digit percentage points as the NBI breached...

Pandemic-driven market volatility has stymied follow-on activity the past two months, but stabilizing markets and big inflows are opening a window of opportunity, at least in the near term. The unfolding consequences of COVID-19 could...